Inhibiting EGFR either with small molecule inhibitors such as the EGFR tyrosine kinase inhibitors gefitinib or erlotinib or with anti-EGFR antibodies such as cetuximab has given promising results in HCC cell lines and in animal studies. The gene discussed is EGFR; the disease is hepatocellular carcinoma.